Transforming mental health
Our lead drug candidate is a fixed-dose combination of an SSRI and a micro-dose of ibogaine – a central nervous system stimulant.
Ibogaine is a powerful compound derived from the root bark of the iboga tree (Tabernanthe iboga), native to Central and West Africa.
Historically, it was marketed in France until the 1970s under the name Lambarène as a stimulant.
Today, ibogaine is at the forefront of cutting-edge research in the United States, being developed not only as a promising treatment for addiction but also for its potential to revolutionize depression therapy by enhancing neuroplasticity and addressing treatment-resistant cases.